Breath is Life. To breathe is to sing, to be able to work or play, to enjoy living to the fullest. But unfortunately, it is estimated that more than one billion people worldwide suffer from chronic respiratory diseases.

Cipla is proud of its commitment to respiratory diseases  with the introduction of Salbutamol tablets in 1976 and Salbutamol inhaler in 1978 in India. Since then we have consistently introduced new products for asthma, Chronic Obstructive Pulmonary Disease (COPD) and Allergic Rhinitis (AR) and more recently in other diseases such as Pulmonary Arterial Hypertension (PAH), lung cancer and Idiopathic Pulmonary Fibrosis (IPF).

Our dedication to Respiratory shows in how our scientists work tirelessly to develop easier-to-use inhaler devices, combination products and devices for monitoring airway diseases. You see evidence of it in the many world firsts we have developed in this therapy. In the incomparable work we have done with the medical fraternity to shatter myths, spread awareness and empower patients to lead fuller lives.

Whether millions are affected or a few hundreds, we take our mission in Respiratory very seriously. No effort is spared to make our products and doctor/patient services easier, better, more useful.

Cipla Respiratory products are available across the world, prescribed by physicians and consumed by patients in over 100 countries. A true testimony to our world-class quality.

Cipla Respiratory. Every breath for our patients, our physicians, our partners.

Notable Achievements
  • World’s largest range of  inhaled medication and devices.
  • We manufacture over 100 million inhalers annually.
  • Respiratory products exported to over 100 countries – Every minute someone somewhere is using a Cipla medication or a delivery system.
  • Commitment to Clinical Trials & Clinical Research – Conducted over 25 drug trials for various drugs and combinations in asthma, COPD and Allergic Rhinitis, and inhaler devices. Plus in vitro studies of drugs and inhaler devices. We also provide support for academic research in respiratory medicine. This includes projects related to air quality, epidemiology of obstructive airway disease and the respiratory health status of urban slum dwellers in India.
  • Founded the Chest Research Foundation in Pune, with the twin objectives of promoting respiratory research and training in India.  It is one of the few such Institutes in the world and is now an independent organization which collaborates with leading institutions around the world.
  • CME activities for professional updation of physicians – Unique initiatives  for different  levels of specialization from primary care to respiratory specialists in the form of workshops, symposia, lectures, and opportunities to interact with global leaders in respiratory medicine.
  • An array of patient awareness and support programmes under Breathefree. Like, a website dedicated to educate patients on asthma, COPD and allergic rhinitis, Breathefree Care & Educators who play an important role in device demonstration and counseling, and Breathefree camps and clinics among other activities.

As you can see, we are constantly pushing the boundaries of science and technology so that someone somewhere in the world breathes better.

Pioneer of many world firsts
  • DP Haler – The world’s first transparent dry powder inhaler.
  • Zerostat V Spacer – World’s first static-free spacer with valve mechanism.
  • World’s first single-action, multi-dose (Salmeterol + Fluticasone/Formoterol + Budesonide) Dry Powder Inhaler.
  • World’s first Tiotropium in MDI for COPD.
  • World’s first breath-actuated inhaler containing a combination of an inhaled corticosteroid and long-acting beta agonist – (Salmeterol + Fluticasone/Formoterol + Budesonide).
  • World’s first combination of 2 long-acting bronchodilators (Tiotropium + Formoterol) for COPD.
  • World’s first 3-in-1 combination inhaler for COPD.
  • World’s first combination of an antihistamine and an intranasal steroid (INCS) for allergic rhinitis in a nasal spray.
  • World’s first generic Bosentan for management of Pulmonary Arterial Hypertension (PAH).
  • The world’s first generic Sildenafil for PAH.
  • The world’s first generic Pirfenidone, the first approved drug for IPF.